Precigen (PGEN) revenue breakdown
By segment, Biopharmaceuticals is the largest at 55% of fiscal 2022 revenue; Exemplar grew fastest, 20% a year over 3 years.
By product, Exemplar is the largest at 89% of fiscal 2024 revenue.
Revenue by segment
Fiscal years, as Precigen reports them in its 10-K filings; fiscal 2022 total $27M.
| Segments | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | Share |
|---|---|---|---|---|---|---|---|
| Biopharmaceuticals | — | — | — | $22M | $922,000 | $15M | 55% |
| Exemplar | — | — | $7M | $10M | $13M | $12M | 45% |
| Trans Ova | $80M | $75M | $70M | — | — | — | — |
| All Other | $59M | — | — | — | — | — | — |
| PGEN Therapeutics | $53M | — | — | — | — | — | — |
| PGEN Therapeutics | — | $29M | — | — | — | — | — |
| MBP Titan | $14M | — | — | — | — | — | — |
| ActoBio | $13M | $7M | — | — | — | — | — |
| All Other | — | — | $5M | — | — | — | — |
Revenue by product
Fiscal years, as Precigen reports them in its 10-K filings; fiscal 2024 total $4M.
| Products | 2016 | 2017 | 2018 | 2024 | Share |
|---|---|---|---|---|---|
| Exemplar | — | — | — | $4M | 89% |
| Exemplar | — | — | — | $422,000 | 11% |
| Collaborations and licenses | $110M | $146M | $77M | — | — |
| Service | $43M | $51M | $52M | — | — |
| Product | $37M | $34M | $29M | — | — |
| Other | $1M | $1M | $3M | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for PGEN.
Open PGEN in InvestinglyQuestions
Where does Precigen make its money?
In fiscal 2022, by segment: Biopharmaceuticals $15M, Exemplar $12M.
From Precigen's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.